Cardinal Health Inc (CAH) company profile
Close on Nov 17, 2026Market cap $64.95BP/E 38.6Yield 0.73%
About Cardinal Health
Wholesale-Drugs, Proprietaries & Druggists' Sundries, SIC 5122
The company operates across multiple healthcare and medical solution units, including Pharmaceutical and Specialty Solutions, GMPD, Nuclear and Precision Health Solutions, AtHome Solutions, and OptiFreight Logistics. Through these segments, the business provides pharmaceutical distribution, specialty healthcare services, precision health offerings, at-home patient care supplies, and logistics solutions. Its client and partner relationships include healthcare institutions, group purchasing organizations, and pharmacy providers such as CVS Health Corporation and OptumRx.
Operations and reporting structures span both domestic and international markets, comprising segments located in the United States and non-U.S. jurisdictions. The entity maintains business relationships, credit agreements, and legal liabilities across multiple regional territories, including state, local, and foreign jurisdictions such as Puerto Rico. Specific facility counts, store numbers, and corporate headquarters details are not specified in the provided text.
Summary of the business section of Cardinal Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cardinal Health Inc
- Founded
- 1971
- Headquarters
- Dublin, OH
- Address
- 7000 Cardinal Place 43017
- Phone
- (614) 757-3033
- Website
- www.cardinalhealth.com
- Employees
- 63,900, Jun 30, 2026
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries
- Incorporated in
- Ohio
- Fiscal year ends
- June 30
- Auditor
- Ernst& Young LLP, Grandview Heights, Ohio
Stock & identifiers
- Ticker
- CAH
- Exchange
- NYSE
- IPO date
- Aug 4, 1983
- Shares outstanding
- 233M, Jul 31, 2026
- Public float
- $48.19B, Dec 31, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 3-for-2, Apr 23, 2001; 3-for-2, Nov 2, 1998; 3-for-2, Dec 17, 1996; 5-for-4, Jul 1, 1994; 5-for-4, Oct 1, 1991; 5-for-4, Oct 1, 1990; 5-for-4, Oct 2, 1989; 11-for-10, Sep 9, 1988; 11-for-10, Sep 9, 1987
- SEC CIK
- 721371
- CUSIP
- 14149Y108
- ISIN
- US14149Y1082
- FIGI
- BBG000D898T9
- Share class FIGI
- BBG001S7PC34
- LEI
- CCU46N3GJMF4OK4N7U60
- EIN
- 31-0958666
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Anita A. Zielinski | Chief Accounting Officer | 5,715 |
| Michelle D. Greene | Chief Information Officer | 19,480 |
| Aaron E. Alt | Chief Financial Officer | 20,495 |
| Jessica L. Mayer | Chief Legal/Compliance Officer | 33,076 |
| Stephen M. Mason | CEO, GMPD Segment | 41,766 |
| Deborah Weitzman | CEO, PSS Segment | 78,182 |
| Mary C. Scherer | Chief Accounting Officer | 5,013 |
| Jason M. Hollar | Chief Executive Officer | 228,926 |
| Valerie Christine Pitteroff | Chief Human Resources Officer | 12,220 |
| Ola M. Snow | Chief Human Resources Officer | 15,254 |
| Sudhakar Ramakrishna | Director | 2,871 |
| David C. Evans | Director | 16,128 |
| Akhil Johri | Director | 22,869 |
| Sheri H. Edison | Director | 15,603 |
| Robert Azelby | Director | 4,840 |
| Patricia Hemingway Hall | Director | 29,849 |
| Robert W. Musslewhite | Director | 2,871 |
| Nancy Killefer | Director | 28,379 |
| Christine Mundkur | Director | 8,291 |
| Michelle Brennan | Director | 8,841 |
| Gregory B. Kenny | Director | 64,194 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 | $22.57M | $74.00M | $5.95M | $463 | $137 |
| FY2025 | $18.98M | $72.78M | $5.35M | $324 | $114 |
| FY2024 | $25.65M | $28.30M | $5.98M | $186 | $121 |
| FY2023 Hollar | $18.79M | $40.80M | $4.15M | $176 | $109 |
| FY2023 Kaufmann | $3.53M | $12.95M | $4.15M | $176 | $109 |
| FY2023 Mr Kaufmann | $3.53M | $12.89M | $4.15M | $176 | $109 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2026
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Jason M. Hollar Chief Executive Officer | $1.50M | $16.26M | $4.28M | $535.68K | $22.57M | +19% |
| Aaron E. Alt Chief Financial Officer | $896.23K | $4.32M | $1.61M | $38.00K | $6.86M | +10% |
| Stephen M. Mason Chief Executive Officer, Global Medical Products and Distribution Segment | $761.99K | $3.40M | $1.11M | $14.40K | $5.29M | +12% |
| Deborah L. Weitzman Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment | $770.48K | $4.06M | $1.25M | $30.40K | $6.12M | +11% |
| Jessica L. Mayer Chief Legal and Compliance Officer | $741.23K | $3.56M | $1.21M | $27.92K | $5.53M | +12% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of June 30, 2026, we had approximately 63,900 employees globally, of which approximately:”
Corporate history
Events identified from SEC filings
See a number that looks wrong?